• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Neurol . Immune-mediated neurological syndromes in SARS-CoV-2-infected patients

tetano

Editor, Senior Moderator
J Neurol


. 2020 Jul 30.
doi: 10.1007/s00415-020-10108-x. Online ahead of print.
Immune-mediated neurological syndromes in SARS-CoV-2-infected patients


Antoine Guilmot[SUP] 1 [/SUP], Sofia Maldonado Slootjes[SUP] 1 [/SUP], Amina Sellimi[SUP] 1 [/SUP], Maroussia Bronchain[SUP] 1 [/SUP], Bernard Hanseeuw[SUP] 1 [/SUP], Leila Belkhir[SUP] 2 [/SUP], Jean Cyr Yombi[SUP] 2 [/SUP], Julien De Greef[SUP] 2 [/SUP], Lucie Pothen[SUP] 2 [/SUP], Halil Yildiz[SUP] 2 [/SUP], Thierry Duprez[SUP] 3 [/SUP], Catherine Fill?e[SUP] 4 [/SUP], Ahalieyah Anantharajah[SUP] 4 [/SUP], Antoine Capes[SUP] 5 [/SUP], Philippe Hantson[SUP] 5 [/SUP], Philippe Jacquerye[SUP] 6 [/SUP], Jean-Marc Raymackers[SUP] 6 [/SUP], Frederic London[SUP] 7 [/SUP], Souraya El Sankari[SUP] 1 [/SUP], Adrian Ivanoiu[SUP] 1 [/SUP], Pietro Maggi[SUP] 1 [/SUP], Vincent van Pesch[SUP] 8 [/SUP]



Affiliations

Abstract

Background: Evidence of immune-mediated neurological syndromes associated with the severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection is limited. We therefore investigated clinical, serological and CSF features of coronavirus disease 2019 (COVID-19) patients with neurological manifestations.
Methods: Consecutive COVID-19 patients with neurological manifestations other than isolated anosmia and/or non-severe headache, and with no previous neurological or psychiatric disorders were prospectively included. Neurological examination was performed in all patients and lumbar puncture with CSF examination was performed when not contraindicated. Serum anti-gangliosides antibodies were tested when clinically indicated.
Results: Of the 349 COVID-19 admitted to our center between March 23rd and April 24th 2020, 15 patients (4.3%) had neurological manifestations and fulfilled the study inclusion/exclusion criteria. CSF examination was available in 13 patients and showed lymphocytic pleocytosis in 2 patients: 1 with anti-contactin-associated protein 2 (anti-Caspr2) antibody encephalitis and 1 with meningo-polyradiculitis. Increased serum titer of anti-GD1b antibodies was found in three patients and was associated with variable clinical presentations, including cranial neuropathy with meningo-polyradiculitis, brainstem encephalitis and delirium. CSF PCR for SARS-CoV-2 was negative in all patients.
Conclusions: In SARS-Cov-2 infected patients with neurological manifestations, CSF pleocytosis is associated with para- or post-infectious encephalitis and polyradiculitis. Anti-GD1b and anti-Caspr2 autoantibodies can be identified in certain cases, raising the question of SARS-CoV-2-induced secondary autoimmunity.

Keywords: Anti-GD1b; Cerebrospinal fluid; Encephalitis; SARS-CoV-2.
 
Back
Top Bottom